Finally, the mechanistic pathways through which GPR affects the immune and inflammatory responses in MM-TBI remain unclear, thus limiting the clinical applicability of GPR as a predictive biomarker and necessitating further experimental studies. The gene discussed is ALDH18A1; the disease is Miyoshi myopathy.